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motherapy improves overall survival but at the expense of substantial 
toxicity. The MAGE-A3 gene is expressed speciﬁcally in tumor cells 
with no expression in normal cells. Pilot studies evaluating the MAGE-
A3 cancer immunotherapeutic (i.e. MAGE-A3 recombinant protein 
combined with a potent GSK proprietary immunological adjuvant) 
showed a good tolerability and long-lasting clinical objective responses 
in metastatic melanoma. Because MAGE-A3 is signiﬁcantly expressed 
in NSCLC (35% in stages IB or II), post-operative immunization with 
the MAGE-A3 cancer immunotherapeutic may be a tumor-speciﬁc, 
well tolerated, and effective adjuvant therapy.
Methods: Patients with completely resected, MAGE-A3 (+), patho-
logical stage IB or II NSCLC were randomly assigned to postoperative 
intramuscular administrations of MAGE-A3 or placebo (2:1), with 5 
administrations at 3-week intervals, followed by 8 administrations ev-
ery 3 months. Stratiﬁcation factors included stage (IB vs. II), histology 
(squamous carcinoma vs. other), and lymph-node procedure (minimal 
lymph-node sampling vs. radical mediastinal lymphadenectomy). The 
primary endpoint was disease-free interval; secondary endpoints were 
safety, disease-free survival, and overall survival. This Phase II study 
(study ID249553/004/NCT00290355) was designed to detect a clini-
cally relevant hazard ratio with a 10% one-sided α.
Results: 1089 tumor samples were examined, of which 363 expressed 
the MAGE-A3 gene. 182 patients (122 stage IB, 60 stage II) from 59 
centers in 14 European countries were randomized over 2 years. The 
patient characteristics are the following: Median age 63 (45-81); 87% 
male; 65% squamous cell carcinoma; 65% systematic radical medi-
astinal lymphadenectomy. After a median follow-up of 28 months, 67 
recurrences were observed. Group comparisons of disease-free interval, 
disease-free survival, and overall survival gave respectively a hazard 
ratio of 0.74 (95% CI 0.44-1.20, p=0.107), 0.73 (95% CI 0.45-1.16, p = 
0.093) and 0.66 (95% CI 0.36-1.20, p = 0.088) in favor of the MAGE-
A3 group. Overall, treatment was well tolerated. Subset analysis sug-
gests that systematic radical mediastinal lymphadenectomy may have a 
positive effect on survival.
Conclusions: The ﬁnal analysis of this randomized Phase II study 
shows a positive signal for clinical activity of MAGE-A3 cancer im-
munotherapeutic as adjuvant treatment in completely resected Stage 
IB or II NSCLC. The relative improvement in disease-free interval and 
disease-free survival is 27%. This treatment is well tolerated. Further 
Phase III evaluation in early NSCLC is planned for 2007.
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Background: Bcl-2 protein is a fundamental cause of tumor cell ac-
cumulation and resistance to anticancer therapy. Oblimersen (Genas-
ense®), a Bcl-2 antisense oligonucleotide, selectively targets bcl-2 RNA 
for degradation by RNase H and thus decreases Bcl-2 protein produc-
tion. Oblimersen enhances the activity of anticancer agents (including 
docetaxel) in animal models, including NSCLC. Findings in clinical 
studies conducted in patients with various solid tumors and hemato-
logic malignancies support this effect.
Methods: A multicenter, randomized study of docetaxel versus 
docetaxel plus oblimersen was conducted in patients with NSCLC who 
had received not more than 1 prior exposure to cytotoxic chemotherapy 
and had relapsed after or were refractory to that therapy. Patients were 
≥ 18 years of age and had measurable disease (Stage IIIB or IV) not 
previously irradiated, ECOG performance status ≤ 2, adequate organ 
function, and a life expectancy ≥ 12 weeks. Key exclusion criteria 
were untreated or symptomatic brain metastases, peripheral neu-
ropathy ≥ Grade 2, and prior radiation therapy to ≥ 25% of the bone 
marrow. Patients were stratiﬁed based on 3 factors (response to prior 
chemotherapy, ECOG performance status [0 or 1 versus 2], and prior 
paclitaxel treatment [yes versus no]) and then centrally randomized at 
a 1:1 ratio. Patients received docetaxel 75 mg/m2 on Day 1 by IV infu-
sion or oblimersen 7 mg/kg/d on Days 1 to 7 by continuous IV infusion 
plus docetaxel 75 mg/m2 on Day 5 of each 21-day cycle for up to 8 
cycles. Patients were assessed for response prior to Cycles 3, 5, and 7, 
at completion of treatment, and up to 18 months after randomization. 
Endpoints include time to progression, survival at 6 and 12 months post 
randomization, response rate (complete and partial), response duration, 
and safety.
Results: Of 298 patients randomized, 287 initiated treatment. Among 
all patients randomized, the median age was 63 years, and 61% of 
patients were male. A total of 86% of patients had Stage IV disease; 
94% had metastatic disease; and 91% had an ECOG performance status 
of 0 or 1. Prior radiotherapy was reported for 39% of patients and prior 
paclitaxel therapy for 48%. Grade 4 neutropenia of 23% among all 
treated patients compared favorably with that historically reported with 
docetaxel alone.
Conclusions: The database will be unblinded in Quarter 2, 2007, and 
results presented.
B1-07 Novel Therapeutics I, Tue, 13:45 - 15:30
Decreased neurocognitive progression with Motexafin Gadolinium 
(MGd) plus Whole Brain Radiation Therapy (WBRT) in non-small 
cell lung cancer (NSCLC) patients with brain metastases: pooled 
analysis of two randomized phase 3 trials
Mehta, Minesh1 Leibenhaut, Mark2 Suh, John3 Meyers, Christine4 
Renschler, Markus F.5 Smith, Jennifer5 Phan, See C.5 
1 University of Wisconsin, Medical School, Madison, WI, USA 2 Sutter 
Cancer Center Radiation Oncology Center, Sacramento, CA, USA 3 
Cleveland Clinic Foundation, Cleveland, OH, USA 4 M.D. Anderson 
Cancer Center, Houston, TX, USA 5 Pharmacyclics, Sunnyvale, CA, 
USA 
Background: In two randomized studies, MGd when combined with 
WBRT prolonged time to progression of neurologic endpoints in 
NSCLC patients (pts) with brain metastases (BM). Neurocognitive test-
ing, which has been shown to correlate with clinical outcome in brain 
tumor patients, was performed in both studies. The purpose of this 
analysis was to pool the neurocognitive data from both trials.
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Methods: In protocol 9801, 401 pts with BM from any primary tumor 
were randomized to receive WBRT alone (30 Gy/10 fractions) or MGd, 
5 mg/kg qd x 10 days, with WBRT. The subgroup of 251 pts with 
NSCLC is included in this analysis. In protocol 0211, 554 pts with BM 
from NSCLC were randomized to the same treatments. In both studies, 
eligibility included a KPS ≥ 70, no liver metastases, and ≤ 1 site of 
extracranial metastasis. In both studies, patients underwent a battery of 
neurocognitive tests measuring memory and executive function at base-
line and all subsequent monthly follow-up visits. Progressions were 
deﬁned as a conﬁrmed decline from baseline of 1.5 standard deviations, 
corrected for age and educational background.
Results: 805 pts received WBRT (N=403) or MGd+WBRT (N=402). 
Most pts had multiple BM (81%), extracranial metastases (47%) 
and presented with neurologic deﬁcits (84%). Treatment arms were 
balanced for key prognostic factors. At baseline, 77% of all patients 
had some degree of neurocognitive deﬁcit with 18% having one test 
result abnormal, 20% having two, 18% having three, 16% having four 
and 5% having all ﬁve test results abnormal. Memory was the most 
frequently impaired function (57%). Baseline neurocognitive impair-
ments were balanced across treatment arms. Patients treated with 
MGd+WBRT were less likely during follow-up to show evidence of 
neurocognitive progression in memory function (HR=0.80, p=0.047), 
in executive function (HR=0.74, p=0.028) or in a combined score for 
all tests, (HR=0.78, p=0.02).
Conclusions: Consistent with the delay in time to clinical neuro-
logic progression seen in a previous pooled analysis, treatment with 
MGd+WBRT decreased progression in each function measured by 
standardized neurocognitive testing in the pooled dataset from 2 ran-
domized phase III trials.
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Background: In early stage NSCLC, neoadjuvant chemotherapy is a 
promising option, although conclusive evidence is yet to be supplied. 
The NATCH trial was designed in order to address whether neoadjuvant 
or adjuvant paclitaxel(P)/carboplatin(C)improves disease-free survival 
compared to surgery alone in early-stage NSCLC. Analyses of toxicity, 
response rate, resectability rate and surgical mortality rates have now 
been carried out on patients randomized to the neoadjuvant arm.
Methods: Clinical stage I (> 2 cm), II, T3N1 NSCLC consenting 
patients are randomized to surgery alone or 3 cycles of neoadjuvant PC 
(P:200 mg/m2/ C AUC:6 on day 1 every 3wk), or surgery followed by 3 
cycles of adjuvant PC at the same schedule. This prospective, random-
ized trial planned to include 624 patients.
Results: Between April 2000 and March 2007, 623 patients have been 
accrued, 201 on the neoadjuvant arm; 211 on the adjuvant arm and 
211 on the surgery arm. On the neoadjuvant arm, demographic data is 
now available for 162 patients: 89% male; median age 64 years (range, 
37-78); 45% PS 0; 53% squamous cell, 27% adenocarcinoma, 13% 
large cell; 7% stage IA, 64% IB, 2% IIA, 24% IIB, 2.5% T3N1. To 
date, neoadjuvant chemotherapy has been well tolerated. No unex-
pected toxicities have been seen with 12% of patients having grade 3-4 
neutropenia and 43% grade 1-2 anemia. Major radiographic response 
has been observed in 59% of patients and progression during chemo-
therapy occurred in 6%. No patient characteristics were predictive for 
clinical response. At thoracotomy resection procedures were: lobec-
tomy or bilobectomy in 70%; pneumonectomy in 26%; and explorative 
thoracotomy due to unresectable disease in 3% of patients. Thirty-day 
post-operative mortality was 4%. At surgery, 9% patients had patho-
logic complete response; 75% N0-1 disease (with persistent T tumor), 
and 15% had pathologic N2 disease. 
Conclusion: Our ﬁndings suggest that neoadjuvant chemotherapy 
in early NSCLC is feasible with manageable toxicity and with good 
resectability rates. Mature survival results of the NATCH trial are 
expected in 2009.
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Background: Surgery offers the best chance of cure for patients with 
NSCLC, but the 5-year survival rate is modest, and improvements are 
urgently required. Following striking results in favour of neo-adjuvant 
chemotherapy in 2 small trials, the current trial was designed to investi-
gate whether, in patients with operable NSCLC of any stage, platinum-
based chemotherapy given prior to surgery would improve outcomes.
Methods: The primary endpoint was overall survival, and secondary 
endpoints were: quality of life, pathological staging, resectability rates, 
extent of surgery, and time to and site of relapse. The trial was designed 
to detect a 15% improvement in 3-year survival (from 40% to 55%) with 
neo-adjuvant chemotherapy (5% signiﬁcance level, 90% power), which 
required 450 patients and 233 events (deaths). Patients were randomised 
to receive either surgery alone (S), or 3 cycles of platinum-based che-
motherapy prior to surgery (CT-S), clinicians choosing (pre-randomisa-
tion) the chemotherapy from 6 standard regimens. Quality of Life was 
assessed by patients completing the SF-36 questionnaire at baseline 
(pre-randomisation), 6 and 12 months, and then annually to 5 years. 
